These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 17090955

  • 21. Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism.
    Wang G, Liu J, Yang N, Hu Y, Zhang H, Miao L, Yao Z, Xu Y.
    Eur J Intern Med; 2016 Jun; 31():94-8. PubMed ID: 27085392
    [Abstract] [Full Text] [Related]

  • 22. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.
    Erdogan M, Solmaz S, Canataroglu A, Kulaksızoglu M, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C.
    Endocrine; 2010 Jun; 37(3):449-54. PubMed ID: 20960167
    [Abstract] [Full Text] [Related]

  • 23. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study.
    Ross DS.
    Am J Med; 1993 Oct; 95(4):385-8. PubMed ID: 8213870
    [Abstract] [Full Text] [Related]

  • 24. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 25. Plasma levels of adiponectin and soluble thrombomodulin in hypothyroid patients with normal thyroid function following levothyroxine replacement therapy.
    Nagasaki T, Inaba M, Hiura Y, Tahara H, Kumeda Y, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y.
    Biomed Pharmacother; 2005 Dec; 59(10):571-7. PubMed ID: 16202556
    [Abstract] [Full Text] [Related]

  • 26. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.
    Koulouri O, Auldin MA, Agarwal R, Kieffer V, Robertson C, Falconer Smith J, Levy MJ, Howlett TA.
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):744-9. PubMed ID: 21521256
    [Abstract] [Full Text] [Related]

  • 27. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients.
    Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z.
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5765-8. PubMed ID: 16046585
    [Abstract] [Full Text] [Related]

  • 28. Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
    Chadarevian R, Jublanc C, Bruckert E, Giral P, Ankri A, Leenhardt L, Chapman J, Turpin G.
    J Endocrinol Invest; 2005 May; 28(5):398-404. PubMed ID: 16075920
    [Abstract] [Full Text] [Related]

  • 29. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 30. Effect of levothyroxine replacement therapy on paraoxonase-1 and carotid intima-media thickness in subclinical hypothyroidism.
    Kebapcilar L, Comlekci A, Tuncel P, Solak A, Secil M, Gencel O, Sahin M, Sari I, Yesil S.
    Med Sci Monit; 2010 Jan; 16(1):CR41-7. PubMed ID: 20037493
    [Abstract] [Full Text] [Related]

  • 31. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
    Mazur P, Sokołowski G, Hubalewska-Dydejczyk A, Płaczkiewicz-Jankowska E, Undas A.
    Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
    [Abstract] [Full Text] [Related]

  • 32. Levothyroxine replacement in hypothyroid humans reduces myocardial lipid load and improves cardiac function.
    Scherer T, Wolf P, Winhofer Y, Duan H, Einwallner E, Gessl A, Luger A, Trattnig S, Hoffmann M, Niessner A, Baumgartner-Parzer S, Krššák M, Krebs M.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2341-6. PubMed ID: 25105733
    [Abstract] [Full Text] [Related]

  • 33. Coronary flow reserve after L-thyroxine therapy in Hashimoto's thyroiditis patients with subclinical and overt hypothyroidism.
    Oflaz H, Kurt R, Sen F, Onur I, Cimen AO, Elitok A, Turkmen K, Pamukcu B, Kasikcioglu E, Bugra Z, Mercanoglu F, Ozbey N.
    Endocrine; 2007 Dec; 32(3):264-70. PubMed ID: 18224461
    [Abstract] [Full Text] [Related]

  • 34. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    Antovic JP, Rafik Hamad R, Antovic A, Blombäck M, Bremme K.
    Thromb Haemost; 2002 Oct; 88(4):644-7. PubMed ID: 12362237
    [Abstract] [Full Text] [Related]

  • 35. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement.
    Kim SK, Kim SH, Park KS, Park SW, Cho YW.
    Endocr J; 2009 Oct; 56(6):753-8. PubMed ID: 19506325
    [Abstract] [Full Text] [Related]

  • 36. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S.
    Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
    [Abstract] [Full Text] [Related]

  • 37. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
    Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M.
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):551-6. PubMed ID: 12960608
    [Abstract] [Full Text] [Related]

  • 38. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [Abstract] [Full Text] [Related]

  • 39. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 40. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI).
    Morange PE, Juhan-Vague I, Scarabin PY, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, PRIME Study group.
    Thromb Haemost; 2003 Mar; 89(3):554-60. PubMed ID: 12624641
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.